Drug Profile
Ralimetinib - Eli Lilly and Company
Alternative Names: LSN-2322600; LY-2228820; LY2228820 dimesylate; p38 MAP inh; Ralimetinib mesylateLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Centre Jean Perrin; Eli Lilly and Company
- Class 2 ring heterocyclic compounds; Antineoplastics; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ovarian cancer
- Phase I/II Glioblastoma
- No development reported Colorectal cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (PO)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (PO)